May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Concentrations of Radioactivity in Ocular Tissues Following a Single Topical Ocular Dose of 14C–Bromfenac Ophthalmic Solution (XibromTM)
Author Affiliations & Notes
  • T. McNamara
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • G.A. Baklayan
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • H.M. Deshmukh
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • H.M. Patterson
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Regulatory,
  • J.A. Gow
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • Footnotes
    Commercial Relationships  T. McNamara, ISTA Pharmaceuticals®, Inc., E; G.A. Baklayan, ISTA Pharmaceuticals®, Inc., E; H.M. Deshmukh, ISTA Pharmaceuticals®, Inc., E; H.M. Patterson, ISTA Pharmaceuticals®, Inc., E; J.A. Gow, ISTA Pharmaceuticals®, Inc., E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5086. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. McNamara, G.A. Baklayan, H.M. Deshmukh, H.M. Patterson, J.A. Gow; Concentrations of Radioactivity in Ocular Tissues Following a Single Topical Ocular Dose of 14C–Bromfenac Ophthalmic Solution (XibromTM) . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5086.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the distribution of the active pharmaceutical ingredient in XibromTM (bromfenac ophthalmic solution) in ocular tissues.

Methods: : Fifty µl of 14C–bromfenac ophthalmic solution (20–25 µCi) was administered using a calibrated pipette into right eye of each 14–18 randomly assigned New Zealand White rabbit eyes and time of dosing recorded. At various time points, 2 animals, at each time point, were euthanized and aqueous humor as well as the ocular tissues collected. The following ocular samples were analyzed: aqueous humor, vitreous humor, conjunctiva, cornea, lens, iris/ciliary body, sclera, retina and choroid. Ocular tissues were combusted and amount of radioactivity determined by Liquid Scintillation Counting (LSC). Aqueous humor samples were transferred to LSC vials directly and amount of radioactivity determined.

Results: : Peak concentrations of radiolabeled bromfenac were observed in the aqueous humor and most ocular tissues at 2 hours; conjunctiva peaked at 1 hour. Bromfenac concentrations were highest in cornea, conjunctiva and sclera. Similar amounts of radiolabeled bromfenac were detected in aqueous humor, iris/ciliary body, choroid, and to a slightly lesser degree, retina. Bromfenac was observed in all samples at 24 hours ≥ 0.01 µg equivalent/g.

Conclusions: : Significant penetration of bromfenac was observed in all tissues over 24 hours including the retina and sclera, with peak concentrations on or before 2 hours. These results strongly suggest that XibromTM (bromfenac ophthalmic solution) 0.09% may also be effective in treating inflammation of the sclera, choroid and retina.

Keywords: anterior segment • choroid • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×